Experimental Small Molecule Shows Potential in Preventing Meth Relapse

Experimental Small Molecule Shows Potential in Preventing Meth Relapse LA JOLLA, CA March 31, 2017 New research from The Scripps Research Institute (TSRI) suggests that the reason methamphetamine users find it so hard to quit 88 percent of them relapse, even after rehab is that meth takes advantage of the brain's natural learning process. The TSRI study in rodent models shows that ceasing meth use prompts new neurons to form in a brain region tied to learning and memory, suggesting that the brain is strengthening memories tied to drug-seeking behavior.

New neuronal growth is normally thought of as a good thing, but we captured these new neurons assisting with bad' behaviors, said Chitra Mandyam, who led the research as an associate professor at TSRI before starting a new position at the Veterans Medical Research Foundation and the University of California, San Diego.

The scientists discovered that they could block relapse by giving animals a synthetic small molecule to stop new neurons from forming. This molecule, called Isoxazole-9 (Isx-9), also appeared to reverse abnormal neuronal growth that developed during meth use.

The new research was published this week in the journal Molecular Psychiatry.

Young Neurons Gone Bad

Neurons are born all the time in a process called neurogenesis. In a 2010 study, Mandyam and her colleagues at TSRI showed that increased neurogenesis is tied to a higher risk of drug relapse, but they weren't sure of the new neurons' role in the process. The researchers were especially curious about a burst of neurogenesis that occurs during abstinence from meth.

The new study may explain why the brain is so eager to make neurons during abstinence: meth hijacks the natural neurogenesis process.

Normally, new neurons help us learn by forming new circuits to connect rewards, like food, to reward-associated memories. For example, we learn early on that the refrigerator holds food. In a non-drug environment, this is a healthy process, said Mandyam.

But the brain isn't good at separating healthy rewards from the dangerous high of drug use.

Using rat models of meth addiction, the researchers showed that forced abstinence prompted the development of new neurons called granule cell neurons in a brain region called the dentate gyrus, which is associated with memory formation. These new neurons drove compulsive-like drug seeking and relapse by strengthening drug-associated memories. The rats learned to associate a particular location in their environment with meth use. Returning to this location during abstinence later served as a triggering cue prompting a recovering addict to relapse.

A Potential Way to Stop Relapse

Next, the researchers tested whether the synthetic small molecule Isx-9 could inhibit this process. Previous studies had shown that Isx-9 could block cell division of some types of cells, but it had not been tested as a way to block neurogenesis and fight meth relapse.

Working closely with Professor Kim Janda's lab at TSRI, which supplied the molecule, Mandyam and her colleagues found that meth-addicted rats given Isx-9 during abstinence were less likely to relapse into drug use. Isx-9 indeed blocked neurogenesis, appearing to keep their brains from strengthening drug-associated memories. For these rats, the environment where they took the drug was no longer a strong trigger for relapse.

Interestingly, the researchers only saw the benefits of Isx-9 in rats that were high responders to meth. From the beginning of the experiment, some of the rats were simply not as interested in the drug Mandyam called them the casual users. Just like humans, animals also show remarkable individual differences in drug seeking, said Mandyam. She plans to further study these individual differences to better understand how to address addiction and recovery.

Isx-9 also appears to repair some of the structural changes seen in neurons exposed to meth. In high-responder rats, Isx-9 restored the neuronal structures crucial for normal cell signaling.

The researchers also plan to further investigate potential side effects of Isx-9, and Mandyam hopes future studies will set the stage to test Isx-9 in clinical trials for meth addiction.

In addition to Mandyam and Janda, authors of the study, A synthetic small molecule Isoxazole-9 protect against methamphetamine relapse, were first author Melissa H. Galinato of TSRI and UC San Diego; Jonathan Lockner, McKenzie J. Fannon-Pavlich, Jeffery Sobieraj, Miranda C. Staples, Sucharita S. Somkuwar, Atoosa Ghofranian, Sharon Chaing, Alvaro I. Navarro and Anuveer Joea of TSRI; Bryan W. Luikart of Dartmouth College Geisel School of Medicine; Charles Heyser of UC San Diego and George F. Koob of the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism.

The study was supported by the National Science Foundation (grant DGE-1144086), the National Institute on Drug Abuse (grant DA034140) and National Institute on Alcohol Abuse and Alcoholism (grants AA020098 andAA06420).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine work toward their next discoveries. The institutes gradua

LINK:	http://www.scripps.edu/news/press/2017/20170331mandyam.html...
	See more stories from scripps

Most recent headlines